A detailed history of Engineers Gate Manager LP transactions in Co Diagnostics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 11,729 shares of CODX stock, worth $14,426. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,729
Previous 12,119 3.22%
Holding current value
$14,426
Previous $13,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.01 - $1.7 $393 - $663
-390 Reduced 3.22%
11,729 $14,000
Q4 2023

Feb 14, 2024

SELL
$1.0 - $1.5 $1,190 - $1,785
-1,190 Reduced 8.94%
12,119 $16,000
Q2 2023

Aug 14, 2023

BUY
$1.04 - $1.64 $668 - $1,054
643 Added 5.08%
13,309 $14,000
Q1 2023

May 15, 2023

SELL
$1.39 - $3.24 $10,910 - $25,430
-7,849 Reduced 38.26%
12,666 $18,000
Q4 2022

Feb 14, 2023

SELL
$2.32 - $3.68 $69,780 - $110,687
-30,078 Reduced 59.45%
20,515 $51,000
Q3 2022

Nov 14, 2022

BUY
$2.87 - $7.01 $145,201 - $354,656
50,593 New
50,593 $162,000
Q2 2022

Aug 15, 2022

SELL
$3.76 - $6.29 $458,731 - $767,398
-122,003 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.03 - $9.61 $289,265 - $552,651
57,508 Added 89.17%
122,003 $754,000
Q4 2021

Feb 14, 2022

BUY
$8.12 - $10.37 $37,725 - $48,179
4,646 Added 7.76%
64,495 $576,000
Q3 2021

Nov 15, 2021

BUY
$7.48 - $11.38 $138,933 - $211,372
18,574 Added 45.0%
59,849 $582,000
Q2 2021

Aug 16, 2021

BUY
$7.16 - $9.56 $49,225 - $65,725
6,875 Added 19.99%
41,275 $341,000
Q1 2021

May 17, 2021

BUY
$8.52 - $19.21 $293,088 - $660,824
34,400 New
34,400 $328,000
Q2 2020

Aug 17, 2020

SELL
$7.46 - $23.42 $208,865 - $655,713
-27,998 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$0.91 - $17.81 $25,478 - $498,644
27,998 New
27,998 $213,000

Others Institutions Holding CODX

About Co-Diagnostics, Inc.


  • Ticker CODX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 33,781,000
  • Market Cap $41.6M
  • Description
  • Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...
More about CODX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.